SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Twin Vee PowerCats Co. engages in the design, manufacture, and sale of recreational and commercial power catamaran boats. The firm is focused on designing and developing its products under the ELECTRA Power Sports brand. It operates through the Twin Vee PowerCats and Wizz Banger, Inc. Segments. The Twin Vee PowerCats segment designs, manufactures, and sells recreational and commercial powerboats. The Wizz Banger, Inc. segment refers to a development-stage subsidiary with plans to develop an innovative online marketplace leveraging artificial intelligence (AI) to transform how customers search for and purchase recreational marine assets. The company was founded by Roger Dunshee in 1996 and is headquartered in Fort Pierce, FL.

Twin Vee PowerCats Co

Twin Vee PowerCats is trending as retail traders target its nano-cap float and tight share structure following a recent reverse stock split. Community members are actively comparing the setup to previous short-squeeze runners, betting that low share availability and minimal short interest could catalyze significant volatility.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility as investors weigh a strong earnings beat and market share expansion against concerns over margin pressure and competitive headwinds. The community remains deeply divided, with many long-term holders pointing to institutional manipulation and options pinning as the reasons for the disconnect between robust fundamentals and depressed share prices.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive FDA pre-BLA meeting that validated its regulatory pathway for sonelokimab in hidradenitis suppurativa, fueling community excitement over a potential best-in-class label and expedited timeline. Investors are actively discussing upcoming clinical readouts, including 52-week trial data and adolescent-specific results, which many believe will force a major valuation re-rating and solidify the company as a prime acquisition candidate.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is seeing intense retail interest as investors treat it as a high-growth play in the memory and AI infrastructure space, with many comparing it to previous sector runners like Micron and SanDisk. The stock is being driven by strong community excitement around its niche MRAM technology, recent defense contract news, and the potential for a gamma squeeze fueled by its low float and highly active options flow.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors debate the timing of long-awaited Phase 3 data for its leukemia candidate, with the community actively split between concerns over trial delays and optimism regarding potential curative efficacy and institutional positioning. The core discussion centers on the lack of an announced 80th event as a sign of durable patient survival versus frustration over the companys silence and repeated requests for stock-based compensation.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is experiencing high volatility as investors weigh the positive implications of potential tariff relief against ongoing concerns about supply chain risks and geopolitical tensions. The community is actively debating the stock's valuation, with many bullish participants viewing recent price dips as a generational buying opportunity while others express frustration over inconsistent short-term price action and manipulation fears.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending as retail investors focus on the company's dual role in stablecoin infrastructure and its potential as an AI-driven fintech platform, buoyed by positive sentiment around upcoming earnings and legislative developments. Community discussions are heavily centered on the stock's recent volatility, its technical setup for a potential rebound, and the broader institutional adoption of USDC.

Applied Digital Corporation

Applied Digital is trending as investors capitalize on massive AI infrastructure expansion and institutional interest, with the community actively debating whether to hold through potential volatility or lock in gains. Traders are closely monitoring upcoming sector earnings for potential ripple effects, while long-term shareholders remain focused on the company's substantial contracted lease pipeline.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense investor interest as the stock remains a central focus in the AI optical infrastructure supercycle, with traders debating whether its recent explosive valuation is justified by long-term capacity ramps or if it faces a potential correction ahead of earnings. Community discussion is sharply divided between believers in the company's structural expansion into 800G and 1.6T production and skeptics highlighting concerns over accounting history, profitability, and high-beta volatility.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors react to bullish catalysts including positive regional delivery growth, production scaling for robotics, and market sentiment surrounding the company's integration into broader AI and autonomous infrastructure ecosystems. The community is actively debating the stock's high valuation against future growth potential, with traders closely monitoring key breakout levels and options activity as the ticker experiences significant volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer PR Newswire AUSTIN...

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting Genprex Collaborators to...

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy To Be Released at the 2026 ASCO Annual Meeting Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene...

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa Gene Therapy

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa Gene Therapy Genprex Signs Sponsored Research Agreement to Study Biomarkers that May...

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting Genprex Collaborators Present Positive...

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting Genprex Collaborators to Present...

Genprex to Participate at BIO Europe Spring 2026

Genprex to Participate at BIO Europe Spring 2026 Genprex to Participate at BIO Europe Spring 2026 PR Newswire AUSTIN, Texas, March 10, 2026 AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc...

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa Gene Therapy in Combination with Immunotherapies to Treat Cancer

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa Gene Therapy in Combination with Immunotherapies to Treat Cancer Genprex Strengthens Intellectual Property...

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034)  DelveInsight

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast...

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2...

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner on April 1, 2009 and is headquartered in Austin, TX.

Current Price	$0.8615
Prev Close	$0.87
Open	$0.88
Dividend Yield	0.00%
50-Day Moving Average	$1.51
Beta	1.47
Avg. Volume	1.26M
PE Ratio	-0.03

52-Week High	$55.00
52-Week Low	$0.8513
Market Capitalization	$8.01M
EPS (Annual)	-$17.40
Price to Book	0.36
Revenue Per Employee	$0.00

GNPX
Genprex Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GNPX News

GNPXGenprex Inc